Page last updated: 2024-10-26

etodolac and Breast Cancer

etodolac has been researched along with Breast Cancer in 4 studies

Etodolac: A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).
etodolac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.

Research Excerpts

ExcerptRelevanceReference
"Patients with resectable breast cancer planned for initial management with surgical resection were enrolled and took 400 mg of etodolac twice daily prior to surgery."6.80A window-of-opportunity biomarker study of etodolac in resectable breast cancer. ( Blair, SL; Carson, DA; Crain, B; Kato, S; Messer, K; Parker, BA; Pu, M; Schwab, RB; Wallace, AM; Weidner, N, 2015)
" Here, in a phase-II biomarker clinical trial in breast cancer patients (n = 38), we tested the combined perioperative use of the β-blocker, propranolol, and the COX2-inhibitor, etodolac, scheduled for 11 consecutive perioperative days, starting 5 days before surgery."5.27Perioperative inhibition of β-adrenergic and COX2 signaling in a clinical trial in breast cancer patients improves tumor Ki-67 expression, serum cytokine levels, and PBMCs transcriptome. ( Allweis, T; Barshack, I; Ben-Eliyahu, S; Birnbaum, Y; Cole, S; Haldar, R; Lavon, H; Lyons, YA; Shaashua, L; Sharon, E; Sood, AK; Zmora, O, 2018)
"Patients with resectable breast cancer planned for initial management with surgical resection were enrolled and took 400 mg of etodolac twice daily prior to surgery."2.80A window-of-opportunity biomarker study of etodolac in resectable breast cancer. ( Blair, SL; Carson, DA; Crain, B; Kato, S; Messer, K; Parker, BA; Pu, M; Schwab, RB; Wallace, AM; Weidner, N, 2015)
"Etodolac was used for these experiments, and was found to induce cell death in a time dependent manner over a 2."1.32MCF-7 breast cancer cell line grown in agarose culture for study of COX-2 inhibitors in three-dimensional growth system. ( Aulthouse, AL; Kinder, DH, 2004)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (25.00)29.6817
2010's3 (75.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Haldar, R1
Shaashua, L1
Lavon, H1
Lyons, YA1
Zmora, O1
Sharon, E1
Birnbaum, Y1
Allweis, T1
Sood, AK1
Barshack, I1
Cole, S1
Ben-Eliyahu, S1
Schwab, RB1
Kato, S1
Crain, B1
Pu, M1
Messer, K1
Weidner, N1
Blair, SL1
Wallace, AM1
Carson, DA1
Parker, BA1
Roy, D1
Arason, GA1
Chowdhury, B1
Mitra, A1
Calaf, GM1
Kinder, DH1
Aulthouse, AL1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Perioperative Use of a β-adrenergic Blocker, Propranolol, and a COX2 Inhibitor, Etodolac, in Patients Undergoing Resection With Curative Intent for Primary Colon and Rectal Cancer: Effect on Tumor Recurrence and Survival[NCT03919461]Phase 2200 participants (Anticipated)Interventional2019-02-28Recruiting
Perioperative Use of a Beta-adrenergic Blocker and a COX-2 Inhibitor in Patients Undergoing Surgery With Primary Pancreatic Cancer: Intervention Aiming to Reduce Pro-metastatic Processes[NCT03838029]Phase 2210 participants (Anticipated)Interventional2019-11-20Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

2 trials available for etodolac and Breast Cancer

ArticleYear
Perioperative inhibition of β-adrenergic and COX2 signaling in a clinical trial in breast cancer patients improves tumor Ki-67 expression, serum cytokine levels, and PBMCs transcriptome.
    Brain, behavior, and immunity, 2018, Volume: 73

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Biomarkers; Breast Neoplasms; Cell Line, Tumor; Cyclooxyge

2018
Perioperative inhibition of β-adrenergic and COX2 signaling in a clinical trial in breast cancer patients improves tumor Ki-67 expression, serum cytokine levels, and PBMCs transcriptome.
    Brain, behavior, and immunity, 2018, Volume: 73

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Biomarkers; Breast Neoplasms; Cell Line, Tumor; Cyclooxyge

2018
Perioperative inhibition of β-adrenergic and COX2 signaling in a clinical trial in breast cancer patients improves tumor Ki-67 expression, serum cytokine levels, and PBMCs transcriptome.
    Brain, behavior, and immunity, 2018, Volume: 73

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Biomarkers; Breast Neoplasms; Cell Line, Tumor; Cyclooxyge

2018
Perioperative inhibition of β-adrenergic and COX2 signaling in a clinical trial in breast cancer patients improves tumor Ki-67 expression, serum cytokine levels, and PBMCs transcriptome.
    Brain, behavior, and immunity, 2018, Volume: 73

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Biomarkers; Breast Neoplasms; Cell Line, Tumor; Cyclooxyge

2018
A window-of-opportunity biomarker study of etodolac in resectable breast cancer.
    Cancer medicine, 2015, Volume: 4, Issue:10

    Topics: Administration, Oral; Aged; beta Catenin; Biomarkers, Tumor; Breast Neoplasms; Cyclin D1; Cyclooxyge

2015

Other Studies

2 other studies available for etodolac and Breast Cancer

ArticleYear
Profiling of cell cycle genes of breast cells exposed to etodolac.
    Oncology reports, 2010, Volume: 23, Issue:5

    Topics: Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cyclooxygenase Inhibitors; Etodolac; Female; Gene Ex

2010
MCF-7 breast cancer cell line grown in agarose culture for study of COX-2 inhibitors in three-dimensional growth system.
    Cancer letters, 2004, Mar-08, Volume: 205, Issue:1

    Topics: Breast Neoplasms; Cell Culture Techniques; Cell Death; Cell Division; Cell Line, Tumor; Cyclooxygena

2004